The Performance of Top Coronavirus Vaccine Stocks during COVID-19 Pandemic: A Multifractal Analysis


Creative Commons License

Özdemir O.

SOSYOEKONOMI, cilt.31, sa.56, ss.27-46, 2023 (ESCI)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 56
  • Basım Tarihi: 2023
  • Dergi Adı: SOSYOEKONOMI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.27-46
  • İstanbul Gelişim Üniversitesi Adresli: Evet

Özet

This study assesses how the coronavirus pandemic (COVID-19) affects the 5-day week multifractal properties of five vaccine stocks (i.e., Pfizer, BioNTech, Moderna, Johnson&Johnson, and AstraZeneca) using weekday index data ranging from 9 December 2019 to 6 January 2022. The main concern is to document whether the presence of herd investing and the level of market efficiency changed between pre-vaccination (i.e., 9 December 2019 - 8 December 2020) and post-vaccination (i.e., 9 December 2020 - 6 January 2022). The generalised Hurst exponents are calculated through multifractal detrended fluctuation analysis. Overall, the empirical results show multifractality for each vaccine stock during the COVID-19 outbreak. Besides, the efficiency level differs among the vaccine stocks based on multifractal properties. The results indicate that the post-vaccination period is more prone to herd investing in BioNTech and Moderna stocks. Considering the impacts of this far-reaching outbreak, the highest MLM (inefficiency) index value is also attributed to BioNTech before and after the COVID-19 vaccination process.